Speed of the relief of GERD symptoms by acid suppressants in reflux esophagitis

Speed of the relief of GERD symptoms by acid suppressants in reflux esophagitis - The relief of GERD symptom in reflux esophagitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018776

Enrollment

Registered

2015-08-23

Start date

2015-08-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reflux esophagitis

Interventions

Vonoprazan (Takecab) 20 mg once a day in the morning Lansoprazole (Takepron) 30 mg once a day in the morning

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who have given written consent to participate in the study. 2. Patients who are at least 20 years of age. 3. Patients who undergo upper gastrointestinal endoscopy within 2 months from the visit and are found to have reflux esophagitis (Los Angeles classification, Grade A-D)

Exclusion criteria

Exclusion criteria: 1. Patients with conditions that are likely to cause upper abdominal symptoms such as malignant tumors, peptic ulcers and systemic diseases (neurological diseases including Parkinson's disease, metabolic diseases including diabetes, etc). 2. Patients with known causes of upper abdominal symptoms including excessive drinking, overeating, taking NSAIDs, and sever stress. 3. Patients with a history of surgery of the upper gastrointestinal tract including the stomach and esophagus.

Design outcomes

Primary

Measure	Time frame
Time (days) to GERD symptom relief	—

Countries

Japan

Contacts

Public ContactTadayuki Oshima

Hyogo College of Medicine Division of Gastroenterology, Department of Internal Medicine

t-oshima@hyo-med.ac.jp0798-45-6662

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026